Patents Examined by Scott Long
  • Patent number: 11118185
    Abstract: Aspects of the disclosure relate to methods and compositions for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering nucleic acid (for example an interfering RNA) to a subject in order to reduce expression of one or both alleles of an endogenous rho gene (for example a mutant rho allele associated with retinitis pigmentosa) in the subject. In some embodiments, a replacement rho gene that is resistant to the interfering nucleic acid also is delivered to the subject.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: September 14, 2021
    Assignees: University of Florida Research Foundation, Incorporated, The Trustees of the University of Pennsylvania
    Inventors: Alfred S. Lewin, William W. Hauswirth, Michael T. Massengill, William Beltran, Gustavo D. Aguirre, Artur Cideciyan, Samuel Jacobson
  • Patent number: 11111288
    Abstract: This disclosure relates to a chimeric antigen receptor for binding with a tumor specific target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region evolved from a parent protein or a fragment thereof and having a decrease in activity in the assay at the normal physiological condition compared to the activity in the assay under the aberrant condition. A method for producing the chimeric antigen receptor is also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 7, 2021
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11103532
    Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimcrization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: August 31, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Ryan Trowbridge, Edward Hodgkin
  • Patent number: 11098077
    Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
    Type: Grant
    Filed: July 1, 2017
    Date of Patent: August 24, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: David Braun Kanne, Chudi Obioma Ndubaku, Jacob Robert Bruml, Thanh Ngoc Lan Le, Jeffrey McKenna, George Scott Tria, Stephen Canham
  • Patent number: 11098098
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 24, 2021
    Assignee: CureLab Oncology, Inc.
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 11096997
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: August 24, 2021
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 11091756
    Abstract: Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: August 17, 2021
    Assignee: BLUEALLELE CORPORATION
    Inventor: Nicholas J. Baltes
  • Patent number: 11090339
    Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Celularity Inc.
    Inventors: Uri Herzberg, Jodi P. Gurney, Robert J. Hariri
  • Patent number: 11090338
    Abstract: The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue for implantation.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: August 17, 2021
    Assignee: LifeCell Corporation
    Inventors: Aaron Barere, Jerome Connor
  • Patent number: 11085057
    Abstract: The present disclosure provides a system for editing genomic DNA, the system comprising an asymmetric donor DNA template; and methods of editing genomic DNA involving use of an asymmetric donor DNA template. The present disclosure provides a system for editing genomic DNA, the system comprising a Cas9 polypeptide with reduced enzymatic activity; and methods of editing genomic DNA involving use of a Cas9 polypeptide with reduced enzymatic activity.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: August 10, 2021
    Assignee: The Regents of the University of California
    Inventors: Jacob E. Corn, Christopher D. Richardson
  • Patent number: 11078252
    Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: August 3, 2021
    Assignee: University College Cardiff Consultants Ltd.
    Inventors: Andrew Sewell, Garry Dolton
  • Patent number: 11077148
    Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 3, 2021
    Assignee: Vivex Biologics Group, Inc.
    Inventors: Timothy Ganey, Wendy W. Weston, Gaëtan Jean-Robert Delcroix
  • Patent number: 11077208
    Abstract: There is described a new gene therapy approach for treating Wilson's disease in which a nucleic acid molecule is used which comprises a nucleotide sequence encoding for a functional ATP7B protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO: 1. Also described are vectors comprising the nucleotide sequence and methods and uses thereof.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 3, 2021
    Assignee: UCL Business Ltd
    Inventors: Amit Nathwani, Deepak Raj
  • Patent number: 11077147
    Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: August 3, 2021
    Assignee: Vivex Biologics Group, Inc.
    Inventors: Timothy Ganey, Wendy W. Weston, Gaëtan Jean-Robert Delcroix
  • Patent number: 11058575
    Abstract: There is described a method for delivering exogenous biomolecules into an eye. The method generally has the steps of injecting, into a region of the eye, a mixture having a plurality of exogenous biomolecules and a plurality of plasmonic structures, the plasmonic structures having a plasmonic resonance wavelength, the plasmonic structures adjoining membranes of target cells in said region due to said injecting; and irradiating said region of said eye with a laser beam having a wavelength being offset to said plasmonic resonance wavelength, said irradiating causing the plasmonic structures to form pores in said membranes of said target cells, allowing at least some of the exogenous biomolecules to be delivered into the target cells via said pores.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: July 13, 2021
    Assignee: ÉCOLE POLYTECHNIQUE
    Inventors: Michel Meunier, Ariel Wilson, Éric Bergeron, Javier Mazzaferri, Santiago Costantino, Przemyslaw Sapieha
  • Patent number: 11058706
    Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: July 13, 2021
    Assignee: FLAGSHIP PIONEERING INNOVATIONS VI, LLC
    Inventors: Morag Helen Stewart, Catherine Cifuentes-Rojas, Ki Young Paek, Avak Kahvejian, Nicholas McCartney Plugis, Alexandra Sophie De Boer, Erica Gabrielle Weinstein, Sebastian Trousil
  • Patent number: 11053476
    Abstract: Methods, kits and compositions for generating cancer stem cells are provided.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: July 6, 2021
    Assignee: EXOSTEM BIOTEC LTD.
    Inventors: Chaya Brodie, Shlomit Brodie
  • Patent number: 11051499
    Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: July 6, 2021
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Sean Stevens, Andrew J. Murphy, Richard Flavell, Elizabeth Eynon, Jorge Galan, Tim Willinger, Markus Manz, Anthony Rongvaux, George D. Yancopoulos
  • Patent number: 11054413
    Abstract: The present invention provides a device for assaying living cells comprising a substrate, wherein the substrate comprises one or more tethering molecules which adhere to the substrate and are capable of interacting with cell membranes of the cells, wherein the cells maintain a free-floating, non-adherent character when bound to the one or more tethering molecules.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: July 6, 2021
    Assignees: UNIVERSITY OF MARYLAND, COLLEGE PARK, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Stuart Martin, Christopher M. Jewell, James I. Andorko, Elisabeth Lily Sooklal, Rebecca Whipple Bettes, Kristi Chakrabarti
  • Patent number: 11046962
    Abstract: Cells, including stem cells, comprising an autobioluminescent phenotype, wherein the cells emit a luminescent signal in the absence of an exogenous luminescent stimulator, are provided. The luminescent signal may be constitutive, inducible, repressible, or tissue-specific. The cells express a synthetically engineered bacterial luciferase (lux) cassette, i.e., the luxCDABEfrp gene cassette. The cells may comprise luxA, luxB, luxC, luxD, luxE, and flavin reductase. The cells may each express a combined expression level of luxC, luxD, luxE, and flavin reductase that is from ten to forty times greater than a combined expression level of luxA and luxB. Further, methods of making and using the cells comprising an autobioluminescent phenotype are disclosed herein.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: June 29, 2021
    Inventors: Daniel Close, Steven Ripp, Gary Sayler, Michael Conway